Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Qinhuang mixture for treating B cell lymphoma and application of qinhuang mixture

A lymphoma and B cell technology, applied in the direction of medical preparations containing active ingredients, drug combinations, antineoplastic drugs, etc., to achieve the effect of reducing toxic and side effects

Active Publication Date: 2015-09-30
RUIJIN HOSPITAL AFFILIATED TO SHANGHAI JIAO TONG UNIV SCHOOL OF MEDICINE
View PDF1 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

There is still a lack of similar drugs in the field of lymphoma treatment

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Qinhuang mixture for treating B cell lymphoma and application of qinhuang mixture
  • Qinhuang mixture for treating B cell lymphoma and application of qinhuang mixture
  • Qinhuang mixture for treating B cell lymphoma and application of qinhuang mixture

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0074] Example 1 A randomized controlled clinical study of Qinhuang mixture in the treatment of patients with intermediate- and high-risk diffuse large B-cell lymphoma

[0075] 1. Materials and methods

[0076] 1.1 Study population

[0077] Included in this study were untreated patients with intermediate-to-high-risk diffuse large B-cell lymphoma in our hospital. The study used the following screening criteria:

[0078] standard constrain

[0079] ●Patients are not limited to gender, aged 18 to 75 years old;

[0080] ●Must meet the diagnostic criteria of DLBCL. Patients with DLBCL confirmed by immunohistochemical analysis of histopathological sections (positive for CD19, CD20 and CD79a);

[0081] ●International Prognostic Index (IPI): For patients aged >60 years, IPI≥2 points; for patients aged <60 years, aaIPI≥1 point;

[0082] ●Medical records confirm that the patient is an untreated newly diagnosed patient;

[0083] Kanofsky score ≥ 70 points; or Eastern Cooperativ...

Embodiment 2

[0208] Example 2 Effect of Qinhuang Mixture on Immune Function of Patients with Diffuse Large B-cell Lymphoma During Chemotherapy

[0209] 1. Materials and methods

[0210] 1.1 Materials

[0211] Flow Cytometry (Flow Cytometry, FCM): FACS Canto produced by BD Company (Becton Dickinson) of the United States TM Ⅱ, the reagents are CD series produced by B-D Company of the United States.

[0212] 800 Immunochemical System Specific Protein Analyzer and its associated reagents, from Beckman / Couler, USA.

[0213] 1.2 Research Methods

[0214] T cell subsets were detected using monoclonal antibody fluorescent labeling detection and flow cytometry.

[0215] Blood samples: Blood samples (peripheral blood) require anticoagulation, EDTA or heparin can be anticoagulated; volume 2–4mL, refrigerated at 4°C for inspection.

[0216] 1.3 Statistical processing

[0217] The test results are expressed as mean ± standard deviation Means before and after treatment were compared between t...

Embodiment 3

[0245] Embodiment 3 Chinese medicine composition

[0246] 1 part of Scutellaria baicalensis, 1.5 parts of Prunella vulgaris, 0.5 parts of turmeric, 3 parts of Astragalus

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to a traditional Chinese medicine composition for treating B cell lymphoma. The traditional Chinese medicine composition is prepared from such raw materials as baikal skullcap root, selfheal, turmeric and astragalus membranaceus. The invention further provides an application of the traditional Chinese medicine composition. The traditional Chinese medicine composition has the advantages that the curative effect of treating incipient moderately high risk DLBCL by use of an R-CHOP scheme is enhanced and complete relief can be achieved more early, the CR rate of a patient having poor overall functional status KPS is increased, the toxic and side reaction, in particular the non-hematological toxicity, of chemotherapy is relieved, a protection effect can be achieved on CD3+CD4+T cells and CD4+CD28+ cells, and the CD4+ / CD8+ cell ratio can be increased.

Description

technical field [0001] The invention relates to the technical field of traditional Chinese medicines, in particular to a Qinhuang mixture for treating B-cell lymphoma and its application. Background technique [0002] Malignant lymphoma (ML) is a malignant tumor that originates in lymph nodes or extranodal lymphoid tissues. According to whether there are Reed–Sternberg Cells (R–S cells) or their variants in the pathology, they are divided into: Hodgkin Lymphoma (Hodgkin Lymphoma, HL) and non-Hodgkin Lymphoma (non–Hodgkin Lymphoma) Lymphoma, NHL). In my country, NHL accounts for 80–90%, the incidence of lymphoma is 1.39 / 100,000 for men, 0.84 / 100,000 for women, and the mortality rate is 1.5 / 100,000, while HL in the United States accounts for 25%. Over the past three decades, the incidence of NHL has increased at a rate of 4% per year, almost doubling worldwide. In recent years, the incidence of malignant lymphoma in my country has also shown a rapid growth trend, and has be...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K36/9066A61P35/00
Inventor 朱伟嵘赵维莅沈小珩王黎
Owner RUIJIN HOSPITAL AFFILIATED TO SHANGHAI JIAO TONG UNIV SCHOOL OF MEDICINE
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com